clinical trial · NCT03992131
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
Ovarian CancerTriple-negative Breast CancerUrothelial CarcinomaSolid TumorRucaparibLucitanibSacituzumab govitecan
brief summary
This is an open label, Phase 1b/2 study with multiple treatment arms evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of rucaparib in combination with a second anticancer therapy in participants with an advanced/metastatic solid malignancy (Phase 1b), followed by evaluation of the combination in one or more specific participant populations in an expansion phase (Phase 2 cohorts).
started
Jun 28, 2019
primary completion
Mar 8, 2022
completion
Apr 22, 2022
last updated
Jan 16, 2024
official title
SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol